BioLife Research Webinar: September 25, 2025
BioLife Research convened a multi-stakeholder virtual meeting to explore the value of artificial intelligence (AI) platforms in accelerating the discovery of vaccines and therapeutic drugs for prioritized diseases in Africa. The meeting addressed the following critical questions:
- How can artificial intelligence approaches accelerate the discovery of products for prioritized diseases in Africa?
- How can artificial intelligence be applied better to manage the delivery and roll-out of vaccines in Africa?
- What capabilities, networks, and collaborations do we require in Africa to maximize the potential of AI in product development and delivery?
BioLife Webinar Presentations
Dr. Agnes Kiragga
The talk highlights available capacity and infrastructure for utilizing and adopting AI and ML models as well as critically reviewing the challenges and gaps that need to be addressed for African researchers and institutions to fulfill their potential.
Dr. Mathew Chun
The presentation describes the complexities in protecting novel AI-guided inventions across geographies and the intricacies of how regulatory frameworks need to adapt to this new paradigm of AI-supported product development.
Prof. Wallace Bulimo
This in an introductory presentation to set the scene and review how AI has revolutionized biomedical and clinical health research.
Dr. Newton Wahome
The talk is an overview and insights about the different generative AI models and algorithms being used to facilitate the discovery and development of the next generation vaccine immunogens.
Prof. Bernherds Ogutu
This in an enlightening presentation on how AI can accelerate clinical development.
Dr. Lia Hunter and Ina Burgstaller
The talk examines the current status of AI infrastructure stature to support clinical trials in Africa. It also showcases one of the initiatives through Bionabu to train and enhance capacity for clinical trials adopting AI tools.
Dr. Juila Makinde
The talk highlights how AI can be deployed to develop therapeutic products for the burgeoning burden of non-communicable diseases .
